Figure 1 from Liquid and Tissue Biopsies for Identifying <i>MET</i> Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib
<p>Patient prescreening/screening and enrollment. *One (0.3%) patient was enrolled based on local testing in a protocol violation. LBx-negative, negative for <i>MET</i>ex14 skipping in LBx; LBx-positive, positive for <i>MET</i>ex14 skipping in LBx; LBx<sub>N/A<...
Đã lưu trong:
| Tác giả chính: | |
|---|---|
| Tác giả khác: | , , , , , , |
| Được phát hành: |
2025
|
| Những chủ đề: | |
| Các nhãn: |
Thêm thẻ
Không có thẻ, Là người đầu tiên thẻ bản ghi này!
|
| Tóm tắt: | <p>Patient prescreening/screening and enrollment. *One (0.3%) patient was enrolled based on local testing in a protocol violation. LBx-negative, negative for <i>MET</i>ex14 skipping in LBx; LBx-positive, positive for <i>MET</i>ex14 skipping in LBx; LBx<sub>N/A</sub>, no available result for <i>MET</i>ex14 skipping in LBx; TBx-negative, negative for <i>MET</i>ex14 skipping in TBx; TBx-positive, positive for <i>MET</i>ex14 skipping in TBx; TBx<sub>N/A</sub>, no available result for <i>MET</i>ex14 skipping in TBx.</p> |
|---|